Skip to main content

Research Repository

Advanced Search

Novel protein interaction network of human calcitonin receptor-like receptor revealed by label-free quantitative proteomics (2023)
Working Paper
Manolis, D., Hasan, S., Ettelaie, C., Maraveyas, A., O'Brien, D., Kessler, B., …Nikitenko, L. Novel protein interaction network of human calcitonin receptor-like receptor revealed by label-free quantitative proteomics

Background G protein-coupled receptor (GPCR) calcitonin receptor-like receptor (CLR) signalling is implicated in skin-related and cardiovascular diseases, migraine and cancer. However, beyond its agonists and receptor activity-modifying proteins (RA... Read More about Novel protein interaction network of human calcitonin receptor-like receptor revealed by label-free quantitative proteomics.

Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial (2019)
Journal Article
Mosenzon, O., Blicher, T. M., Rosenlund, S., Eriksson, J., Heller, S., Hels, O. H., …Zhdanova, E. (2019). Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes and Endocrinology, 7(7), 515-527. https://doi.org/10.1016/S2213-8587%2819%2930192-5

Background: Oral semaglutide is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist for glycaemic control in patients with type 2 diabetes. Type 2 diabetes is commonly associated with renal impairment, restricting treatment options. We ai... Read More about Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.